Browsing Category
Trending
Cardax clinches deal with HECL for distribution of ZanthoSyn
Cardax asserted that it has forayed into a Purchase Agreement with Health Elite Club limited of Hong Kong for distribution of ZanthoSyn implied for inflammatorry health and longevity in…
Read More...
Read More...
SenzaGen signs licensing agreement with Eurofins BioPharma
SenzaGen asserted that the company has signed a global licensing agreement with leading contract research organization Eurofins BioPharma Product Testing Munich to endorse the GARD test…
Read More...
Read More...
Denali Therapeutics, Lonza Pharma and Biotech extended strategic partnership
Lonza Pharma and Biotech and Denali Therapeutics asserted having entered into a strategic partnership on Denali's biologic pipeline products for neurodegenerative diseases.The agreement…
Read More...
Read More...
Great Point Partners rebukes BioCryst’s BCRX’s merger with Idera Pharmaceuticals
Great Point Partners, LLC submitted a letter to the Board of Directors of BioCryst Pharmaceuticals strongly rebuking BCRX's merger with Idera Pharmaceuticals.
The letter states "We…
Read More...
Read More...
DermTech exhibited PLA against High Risk DNA Mutations
Global leader in non-invasive molecular dermatology, DermTech claimed that the late-breaking abstract, "Validation of Noninvasive Gene Expression (PLA) Against High Risk Driver…
Read More...
Read More...
Photocure declares that FDA approved Blue Light Cystoscopy with Cysview
Photocure ASA asserted that the U.S Food and Drug Administration approved its supplemental new drug application to extend the indication for Blue Light Cystoscopy with Cysview to…
Read More...
Read More...
FDA sanctions IMFINZI for treatment of Stage III NSCLC
AstraZeneca and MedImmune proclaimed that the US FDA has approved IMFINZI (durvalumab) for the treatment of patients with unresectable Stage III non-small cell lung cancer (NSCLC)…
Read More...
Read More...
Lead Cell Medica Financing appointed Kevin S. Boyle as CFO
Cell Medica, asserted the appointment of Kevin S. Boyle, Sr as the Chief Financial Officer, based in Houston, TX. Kevin S. Boyle ushers on board 20 years of financial and capital…
Read More...
Read More...
Shawn M. Cross appointed CEO of GT Biopharma
GT Biopharma focused on the development and commercialization of novel cancer immunotherapy products as well as central nervous system treatments asserted the appointment of Shawn M.…
Read More...
Read More...
FDA commissioner Scott Gottlieb issues statement on influenza vaccine
Influenza Vaccine is one of the best ways known to protect against the flu. However, because of the severity of this season, there have been questions raised about how well this year's…
Read More...
Read More...
Arrowhead sought MEDSAFE for ARO-HBV study
Arrowhead Pharmaceuticals sought approval from the New Zealand Medicines and Medical Devices Safety Authority (MEDSAFE) and from the local Ethics Committee to proceed with a…
Read More...
Read More...
Aravive Biologics begins Phase 1 Clinical Trial of AVB-S6-500
Clinical-stage biotechnology company, Aravive Biologics, Inc aiming to focus on development of treatments for Cancer and fibrotic diseases declared the commencement of Phase 1 clinical…
Read More...
Read More...
Arrowhead Pharmaceuticals seeks Orphan Drug Designation for ARO-AAT
Arrowhead Pharmaceuticals seeks FDA's orphan drug designation to ARO-AAT. Arrowhead’s second-generation investigational medicine for the treatment of a rare genetic liver disease…
Read More...
Read More...
Viz.ai sought De Novo FDA clearance for LVO strokes in CTA imaging
Applied artificial intelligence healthcare company, Viz.ai asserted that the US FDA has extended a De Novo request for the first-ever Computer -Aided Triage and Notification Platform to…
Read More...
Read More...
DreaMed Diabetics attained CE Mark for Platform tackling Type 1 diabetes
DreaMed Diabetes asserted that it received CE Mark for the Advisor Pro decision-support platform for assisting healthcare professionals in the management of Type 1 diabetes.
DreaMed…
Read More...
Read More...
Evofem Biosciences completes enrollment in Phase 3 Clinical Trial for Amphora
Evofem Biosciences aiming to meet women's unmet healthcare needs asserted completion of enrollment in its Phase 3 Clinical Trial evaluating Amphora vaginal gel for the prevention of…
Read More...
Read More...
Citius enrolls first patient in Mino-Lok Phase 3 Clinical trial
Citius Pharmaceuticals emphasizing on adjunctive cancer care and critical care drug products affirmed the enrollment of first patient into the Mino-Lok Phase 3 Clinical Trial for…
Read More...
Read More...
Eisai asserts positive results of Phase 3 Study for lenvatinib mesylate
Eisai declared positive results of Phase 3 study for its discovered and developed anticancer agent lenvatinib mesylate in patients grappling with unresectable hepatocellular carcinoma…
Read More...
Read More...
Merck KGaA and Pfizer assert Phase III JAVELIN Lung 200 trial results
Merck KGaA, Darmstadt, Germany, and Pfizer assert results from the Phase III JAVELIN Lung 200 trial comparing avelumab to docetaxel in patients with unresectable, recurrent or…
Read More...
Read More...
Regentys collaborates with Cook Biotech to curate Unique Ulcerative Colitis Treatment
Regentys, a regenerative medicine company, announced it will partner with Cook Biotech Inc., collaborate to develop a novel treatment for ulcerative colitis.Cook Biotech will develop…
Read More...
Read More...